Boston Scientific Drops Despite Encouraging Trial Readouts

WATCHMAN FLX Shows Bleeding Advantage, Matches EfficacyThe CHAMPION-AF study results shared on Saturday highlighted the WATCHMAN FLX device’s efficacy compared to traditional blood thinners as a first-line option for stroke risk reduction in a broad population of patients with non-valvular atrial fibrillation (NVAF), a common heart rhythm disorder.The CHAMPION-AF trial demonstrated that the WATCHMAN FLX device provided statistically superior protection from bleeding while showing similar efficacy to non-vit ...